Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:associatedWith |
gptkb:PPSV23
gptkb:PCV13 |
| gptkbp:ATCCode |
J07AL06
|
| gptkbp:brand |
Prevnar 20
|
| gptkbp:containsAdjuvant |
no
|
| gptkbp:containsPreservative |
no
|
| gptkbp:containsSerotype |
gptkb:18C
gptkb:19F gptkb:23F 1 3 4 5 8 11A 6B 9V 6A 19A 7F 10A 15B 12F 22F 33F |
| gptkbp:contraindication |
severe allergic reaction to any component
severe allergic reaction to previous dose of PCV |
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
suspension for injection
|
| gptkbp:fullName |
20-valent pneumococcal conjugate vaccine
|
| https://www.w3.org/2000/01/rdf-schema#label |
PCV20
|
| gptkbp:indication |
prevention of invasive disease caused by Streptococcus pneumoniae
pneumococcal bacteremia prevention pneumococcal meningitis prevention pneumococcal otitis media prevention pneumococcal pneumonia prevention |
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:routeOfAdministration |
intramuscular
|
| gptkbp:sideEffect |
fever
fatigue headache joint pain muscle pain injection site pain |
| gptkbp:storage |
2-8°C
|
| gptkbp:targetAudience |
adults 18 years and older
children 6 weeks and older |
| gptkbp:WHOPrequalified |
no
|
| gptkbp:bfsParent |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|